Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pozelimab
- Development stage
- Approved
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Pozelimab is a fully human monoclonal IgG4 antibody used to treat CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease, in adults and children aged 1 year and older. It acts as a complement inhibitor by binding to complement component C5, blocking its cleavage into C5a and C5b, thereby preventing the formation of the membrane-attack complex (C5b-C9) that mediates cell lysis. This mechanism reduces terminal complement activation implicated in CHAPLE disease pathology. Pozelimab is administered via intravenous or subcutaneous injection and was developed using Regeneron's VelocImmune technology[1][2][3][4][5][8].
- Brand names
- Veopoz
- Other names
- pozelimab-bbfg
02
Targets
C5
Beyond the preview
Go deeper on pozelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pozelimab.